{"id":3602,"date":"2026-09-29T09:33:43","date_gmt":"2026-09-29T09:33:43","guid":{"rendered":"https:\/\/clevidence.pt\/?page_id=3602"},"modified":"2026-09-29T09:33:45","modified_gmt":"2026-09-29T09:33:45","slug":"programas-acesso-precoce-portugal-dados","status":"publish","type":"page","link":"https:\/\/clevidence.pt\/pt-pt\/programas-acesso-precoce-portugal-dados\/","title":{"rendered":"Programas de acesso precoce em Portugal: dados do INFARMED 2017-2026"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3602\" class=\"elementor elementor-3602 elementor-3601\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3236f890 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3236f890\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-389caa67\" data-id=\"389caa67\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4fac6b04 elementor-widget elementor-widget-heading\" data-id=\"4fac6b04\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Programas de acesso precoce em Portugal: dados do INFARMED 2017-2026<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-79c7745e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"79c7745e\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1a5d3d07\" data-id=\"1a5d3d07\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-34f8cee2 elementor-icon-list--layout-inline elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"34f8cee2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items elementor-inline-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clevidence.pt\/\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Home<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1024 1024\"><path transform=\"translate(0 960) scale(1 -1)\" d=\"M256 -64Q251 -64 246.5 -62.0Q242 -60 238 -57Q230 -49 230.0 -38.5Q230 -28 238 -20L681 422L238 865Q230 873 230.0 883.5Q230 894 238 901Q245 909 256.0 909.0Q267 909 274 901L735 441Q742 433 742.0 422.5Q742 412 735 404L274 -57Q270 -60 265.5 -62.0Q261 -64 256 -64Z\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Programas de acesso precoce em Portugal: dados do INFARMED 2017-2026<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-277a4ec elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"277a4ec\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-492c9c6\" data-id=\"492c9c6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1a77c98 elementor-widget elementor-widget-text-editor\" data-id=\"1a77c98\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Quantos programas de acesso precoce (PAP) aprova o INFARMED em Portugal, para que doen\u00e7as, e porque s\u00e3o recusados pedidos? Analis\u00e1mos todas as decis\u00f5es da lista oficial de PAP do INFARMED, de dezembro de 2017 a fevereiro de 2026.<\/p>\n<h2>N\u00fameros principais<\/h2>\n<ul>\n<li><strong>170 decis\u00f5es<\/strong> sobre pedidos de PAP entre dezembro de 2017 e fevereiro de 2026.<\/li>\n<li><strong>122 aprovados (72 %)<\/strong>, 40 recusados (24 %) e 8 classificados como n\u00e3o aplic\u00e1veis.<\/li>\n<li><strong>2025 foi um ano recorde:<\/strong> 48 decis\u00f5es, mais do dobro das 23 de 2024.<\/li>\n<li><strong>1 190 doentes<\/strong> nos 112 programas aprovados que indicam o n\u00famero, com uma mediana de 6 doentes por programa.<\/li>\n<li><strong>108 dos programas aprovados aparecem como ativos com custos<\/strong>, e 12 como ativos sem custos.<\/li>\n<li>Cerca de <strong>4 em cada 10 decis\u00f5es s\u00e3o de oncologia e hemato-oncologia<\/strong> (classifica\u00e7\u00e3o nossa das indica\u00e7\u00f5es).<\/li>\n<\/ul>\n<h2>Decis\u00f5es por ano<\/h2>\n<svg viewBox=\"0 0 640 300\" width=\"100%\" role=\"img\" aria-label=\"Decis\u00f5es de PAP por ano\" style=\"max-width:680px;height:auto;font-family:inherit\"><line x1=\"50\" x2=\"630\" y1=\"250\" y2=\"250\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"254\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">0<\/text><line x1=\"50\" x2=\"630\" y1=\"206\" y2=\"206\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"210\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">10<\/text><line x1=\"50\" x2=\"630\" y1=\"162\" y2=\"162\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"166\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">20<\/text><line x1=\"50\" x2=\"630\" y1=\"118\" y2=\"118\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"122\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">30<\/text><line x1=\"50\" x2=\"630\" y1=\"74\" y2=\"74\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"78\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">40<\/text><line x1=\"50\" x2=\"630\" y1=\"30\" y2=\"30\" stroke=\"#e1e6f4\"\/><text x=\"42\" y=\"34\" font-size=\"11\" text-anchor=\"end\" fill=\"#5b6485\">50<\/text><rect x=\"62\" y=\"245.6\" width=\"40\" height=\"4.4\" fill=\"#3490F3\" rx=\"2\"\/><text x=\"82\" y=\"239.6\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">1<\/text><text x=\"82\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2017<\/text><rect x=\"122\" y=\"245.6\" width=\"40\" height=\"4.4\" fill=\"#17224D\" rx=\"2\"\/><text x=\"142\" y=\"239.6\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">1<\/text><text x=\"142\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2018<\/text><rect x=\"182\" y=\"232.4\" width=\"40\" height=\"17.6\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"182\" y=\"228\" width=\"40\" height=\"4.4\" fill=\"#17224D\" rx=\"2\"\/><text x=\"202\" y=\"222\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">5<\/text><text x=\"202\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2019<\/text><rect x=\"242\" y=\"236.8\" width=\"40\" height=\"13.2\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"242\" y=\"228\" width=\"40\" height=\"8.8\" fill=\"#17224D\" rx=\"2\"\/><rect x=\"242\" y=\"210.4\" width=\"40\" height=\"17.6\" fill=\"#a9b4d6\" rx=\"2\"\/><text x=\"262\" y=\"204.4\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">9<\/text><text x=\"262\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2020<\/text><rect x=\"302\" y=\"162\" width=\"40\" height=\"88\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"302\" y=\"157.6\" width=\"40\" height=\"4.4\" fill=\"#17224D\" rx=\"2\"\/><rect x=\"302\" y=\"148.8\" width=\"40\" height=\"8.8\" fill=\"#a9b4d6\" rx=\"2\"\/><text x=\"322\" y=\"142.8\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">23<\/text><text x=\"322\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2021<\/text><rect x=\"362\" y=\"135.6\" width=\"40\" height=\"114.4\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"362\" y=\"113.6\" width=\"40\" height=\"22\" fill=\"#17224D\" rx=\"2\"\/><rect x=\"362\" y=\"109.2\" width=\"40\" height=\"4.4\" fill=\"#a9b4d6\" rx=\"2\"\/><text x=\"382\" y=\"103.2\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">32<\/text><text x=\"382\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2022<\/text><rect x=\"422\" y=\"162\" width=\"40\" height=\"88\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"422\" y=\"131.2\" width=\"40\" height=\"30.8\" fill=\"#17224D\" rx=\"2\"\/><text x=\"442\" y=\"125.2\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">27<\/text><text x=\"442\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2023<\/text><rect x=\"482\" y=\"179.6\" width=\"40\" height=\"70.4\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"482\" y=\"148.8\" width=\"40\" height=\"30.8\" fill=\"#17224D\" rx=\"2\"\/><text x=\"502\" y=\"142.8\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">23<\/text><text x=\"502\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2024<\/text><rect x=\"542\" y=\"109.2\" width=\"40\" height=\"140.8\" fill=\"#3490F3\" rx=\"2\"\/><rect x=\"542\" y=\"43.2\" width=\"40\" height=\"66\" fill=\"#17224D\" rx=\"2\"\/><rect x=\"542\" y=\"38.8\" width=\"40\" height=\"4.4\" fill=\"#a9b4d6\" rx=\"2\"\/><text x=\"562\" y=\"32.8\" font-size=\"12\" font-weight=\"700\" text-anchor=\"middle\" fill=\"#17224D\">48<\/text><text x=\"562\" y=\"268\" font-size=\"11\" text-anchor=\"middle\" fill=\"#5b6485\">2025<\/text><rect x=\"60\" y=\"284\" width=\"12\" height=\"12\" fill=\"#3490F3\"\/><text x=\"78\" y=\"294\" font-size=\"12\" fill=\"#17224D\">Aprovados<\/text><rect x=\"180\" y=\"284\" width=\"12\" height=\"12\" fill=\"#17224D\"\/><text x=\"198\" y=\"294\" font-size=\"12\" fill=\"#17224D\">Recusados<\/text><rect x=\"300\" y=\"284\" width=\"12\" height=\"12\" fill=\"#a9b4d6\"\/><text x=\"318\" y=\"294\" font-size=\"12\" fill=\"#17224D\">Outros<\/text><\/svg><table style=\"border-collapse:collapse;width:100%;max-width:680px\"><thead><tr><th style=\"text-align:left;border-bottom:2px solid #17224D;padding:6px\">Ano<\/th><th style=\"text-align:left;border-bottom:2px solid #17224D;padding:6px\">Decis\u00f5es<\/th><th style=\"text-align:left;border-bottom:2px solid #17224D;padding:6px\">Aprovados<\/th><th style=\"text-align:left;border-bottom:2px solid #17224D;padding:6px\">Recusados<\/th><th style=\"text-align:left;border-bottom:2px solid #17224D;padding:6px\">Outros<\/th><\/tr><\/thead><tbody><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2017<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2018<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2019<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">5<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">4<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2020<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">9<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">3<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">4<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2021<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">23<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">20<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2022<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">32<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">26<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">5<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2023<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">27<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">20<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">7<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2024<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">23<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">16<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">7<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">0<\/td><\/tr><tr><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">2025<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">48<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">32<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">15<\/td><td style=\"padding:6px;border-bottom:1px solid #e1e6f4\">1<\/td><\/tr><\/tbody><\/table>\n<p>2026 inclui apenas uma decis\u00e3o, at\u00e9 \u00e0 \u00faltima atualiza\u00e7\u00e3o da lista, a 19 de mar\u00e7o de 2026.<\/p>\n<h2>Porque s\u00e3o recusados pedidos<\/h2>\n<p>Em 35 das 40 recusas, o INFARMED considerou que a situa\u00e7\u00e3o cl\u00ednica n\u00e3o se enquadrava na exce\u00e7\u00e3o prevista no artigo 25.\u00ba do Decreto-Lei n.\u00ba 97\/2015, que exige, entre outras condi\u00e7\u00f5es, a inexist\u00eancia de alternativa terap\u00eautica satisfat\u00f3ria. A propor\u00e7\u00e3o de recusas subiu em 2025, para 15 em 48 decis\u00f5es.<\/p>\n<h2>Quem paga<\/h2>\n<p>Segundo a Delibera\u00e7\u00e3o n.\u00ba 80\/CD\/2017 do INFARMED, os medicamentos em PAP s\u00e3o, em regra, cedidos sem encargos para o Servi\u00e7o Nacional de Sa\u00fade, com um limite ao per\u00edodo sem encargos para os medicamentos com AIM \u00e0 espera da avalia\u00e7\u00e3o pr\u00e9via. Passado esse per\u00edodo, as condi\u00e7\u00f5es de fornecimento s\u00e3o acordadas com o INFARMED. Por isso a maioria dos programas ativos da lista aparece &#8220;com custos&#8221;. Para as empresas, o acesso precoce \u00e9 um custo real do lan\u00e7amento, que deve ser planeado. Veja o nosso <a href=\"https:\/\/clevidence.pt\/pt-pt\/analise-de-impacto-orcamental-em-portugal\/\">guia sobre a an\u00e1lise de impacto or\u00e7amental em Portugal<\/a>.<\/p>\n<h2>O que isto significa para as empresas<\/h2>\n<ul>\n<li>O acesso precoce \u00e9 muito usado, mas n\u00e3o \u00e9 autom\u00e1tico: um em cada quatro pedidos \u00e9 recusado, sobretudo por n\u00e3o cumprir a exce\u00e7\u00e3o legal.<\/li>\n<li>A oncologia domina, o que reflete tanto os medicamentos em desenvolvimento como a necessidade n\u00e3o satisfeita na doen\u00e7a avan\u00e7ada.<\/li>\n<li>Os programas s\u00e3o pequenos, normalmente poucos doentes cada, e por isso complementam a decis\u00e3o de financiamento, n\u00e3o a substituem.<\/li>\n<\/ul>\n<h2>M\u00e9todo e fonte<\/h2>\n<p>Fonte: <a href=\"https:\/\/www.infarmed.pt\/web\/infarmed\/-\/lista-dos-pap-programa-de-acesso-precoce-a-medicamentos-\" rel=\"noopener\" target=\"_blank\">INFARMED, Lista dos PAP (Programa de acesso precoce a medicamentos)<\/a>, ficheiro atualizado a 19 de mar\u00e7o de 2026 e descarregado a 29 de setembro de 2026. Os n\u00fameros foram contados diretamente na lista. &#8220;Outros&#8221; junta as decis\u00f5es registadas como n\u00e3o aplic\u00e1veis. A divis\u00e3o por \u00e1rea terap\u00eautica \u00e9 nossa, feita por palavras da indica\u00e7\u00e3o aprovada, e \u00e9 aproximada.<\/p>\n<p>Pode reutilizar estes n\u00fameros, citando a Clevidence com uma liga\u00e7\u00e3o para esta p\u00e1gina.<\/p>\n<p>Leia tamb\u00e9m o nosso <a href=\"https:\/\/clevidence.pt\/pt-pt\/guia-acesso-ao-mercado-portugal\/\">guia pr\u00e1tico do acesso ao mercado em Portugal<\/a>, o artigo sobre <a href=\"https:\/\/clevidence.pt\/pt-pt\/avaliacao-de-tecnologias-de-saude-em-portugal-novo-sinats\/\">o novo SiNATS<\/a>, ou conhe\u00e7a os nossos <a href=\"https:\/\/clevidence.pt\/pt-pt\/avaliacao-das-tecnologias-da-saude-ats-e-acesso-ao-mercado\/\">servi\u00e7os de avalia\u00e7\u00e3o de tecnologias de sa\u00fade e acesso ao mercado<\/a>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Quantos programas de acesso precoce (PAP) aprova o INFARMED em Portugal, para que doen\u00e7as, e porque s\u00e3o recusados pedidos? Analis\u00e1mos todas as decis\u00f5es da lista oficial de PAP do INFARMED, de dezembro de 2017 a fevereiro de 2026. N\u00fameros principais 170 decis\u00f5es sobre pedidos de PAP entre dezembro de 2017 e fevereiro de 2026. 122 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-3602","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/pages\/3602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/comments?post=3602"}],"version-history":[{"count":1,"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/pages\/3602\/revisions"}],"predecessor-version":[{"id":3603,"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/pages\/3602\/revisions\/3603"}],"wp:attachment":[{"href":"https:\/\/clevidence.pt\/pt-pt\/wp-json\/wp\/v2\/media?parent=3602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}